Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F8GK
|
|||
| Former ID |
DNCL003804
|
|||
| Drug Name |
LY2886721
|
|||
| Synonyms |
LY2886721; 1262036-50-9; LY-2886721; UNII-2CQ62IWB67; LY 2886721; 2CQ62IWB67; N-(3-((4aS,7aS)-2-amino-4a,5,7,7a-tetrahydro-4H-furo[3,4-d][1,3]thiazin-7a-yl)-4-fluorophenyl)-5-fluoropicolinamide; CHEMBL2396989; N-{3-[(4as,7as)-2-Amino-4a,5-Dihydro-4h-Furo[3,4-D][1,3]thiazin-7a(7h)-Yl]-4-Fluorophenyl}-5-Fluoropyridine-2-Carboxamide; n-(3-((4as,7as)-2-amino-4a,5-dihydro-4h-furo(3,4-d)(1,3)thiazin-7a(7h)-yl)-4-fluorophenyl)-5-fluoro-2-pyridinecarboxamide; NIDRNVHMMDAAIK-YPMLDQLKSA-N; MLS006011070; SCHEMBL966802; GTPL6475
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2 | [1], [2] | |
| Company |
Lilly
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C18H16F2N4O2S
|
|||
| Canonical SMILES |
C1C2CSC(=NC2(CO1)C3=C(C=CC(=C3)NC(=O)C4=NC=C(C=C4)F)F)N
|
|||
| InChI |
1S/C18H16F2N4O2S/c19-11-1-4-15(22-6-11)16(25)23-12-2-3-14(20)13(5-12)18-9-26-7-10(18)8-27-17(21)24-18/h1-6,10H,7-9H2,(H2,21,24)(H,23,25)/t10-,18-/m0/s1
|
|||
| InChIKey |
NIDRNVHMMDAAIK-YPMLDQLKSA-N
|
|||
| CAS Number |
CAS 1262036-50-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
103924900, 104164447, 124360800, 125164713, 136340132, 136348731, 136367586, 137241585, 144116168, 152258479, 160647314, 162011768, 162037543, 163643287, 165246683, 174501978, 174527036, 178103089, 184812176, 189622827, 198972442, 223378377, 223404314, 223705126, 224467053, 227225886, 251963143, 252215741, 252451381
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Beta-secretase (BACE) | Target Info | Modulator | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6475). | |||
| REF 2 | Clinical pipeline report, company report or official report of Eli Lilly. | |||
| REF 3 | Lessons from a BACE1 inhibitor trial: off-site but not off base.Alzheimers Dement.2014 Oct;10(5 Suppl):S411-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.